AIM:To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stageⅢ/Ⅳgastric cancer.METHODS:A total of 53 stageⅢ/Ⅳgastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy.Two of the cases were excluded.The program was as follows:75 mg/m2docetaxel and 85 mg/m2 oxaliplatin on day 1 and 1500mg/m2 fluorouracil on days 1 to 3 for three weeks.RESULTS:The tumour changes,postoperative remission rate,changes in the symptoms and adverse reactions were observed.The overall clinical efficacy(com-plete remission+partial remission)of the neoadjuvant chemotherapy was 62.7%.R0 radical resection was performed on 60.8%of the patients,with a remission rate(pathological complete response+pathological subtotal response+pathological partial response)of74.2%.The Karnofksy score improved in 42 cases.The toxicity reactions mostly included myelosuppression,followed by gastrointestinal mucosal lesions,nausea,vomiting and diarrhoea.CONCLUSION:Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stageⅢ/Ⅳgastric cancer.However,the treatment is associated with a high incidence of bone marrow suppression,which should be managed clinically. AIM: To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III / IV gastric cancer. METHODS: A total of 53 stage III / IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was excluded. The program was as follows: 75 mg / m2docetaxel and 85 mg / m2 oxaliplatin on day 1 and 1500 mg / m2 fluorouracil on days 1 to 3 for three weeks .RESULTS: The changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (com-plete remission + partial remission) of the neoadjuvant chemotherapy was 62.7% .R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. the the kinetics of the reaction included myelosuppression, followed by g astrointestinal mucosal lesions, nausea, vomiting and diarrhea. CONCLUSION: Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III / IV gastric cancer. Although the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically .